🚀 VC round data is live in beta, check it out!
Wantai BioPharm Valuation Multiples
Discover revenue and EBITDA valuation multiples for Wantai BioPharm and similar public comparables like Merus, ALK, Alkem Laboratories, Kymera Therapeutics and more.
Wantai BioPharm Overview
About Wantai BioPharm
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
Founded
1991
HQ
Employees
3.8K
Website
Financials (FY)
EV
$7B
Wantai BioPharm Financials
Wantai BioPharm reported last fiscal year revenue of $329M and EBITDA of $55M.
In the same fiscal year, Wantai BioPharm generated $218M in gross profit, $55M in EBITDA, and $16M in net income.
Revenue (LTM)
Wantai BioPharm P&L
In the most recent fiscal year, Wantai BioPharm reported revenue of $329M and EBITDA of $55M.
Wantai BioPharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $329M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $218M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 66% | XXX | XXX | XXX |
| EBITDA | — | XXX | $55M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 0% | XXX | XXX | XXX |
| Net Profit | — | XXX | $16M | XXX | XXX | XXX |
| Net Margin | — | XXX | 5% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Wantai BioPharm Stock Performance
Wantai BioPharm has current market cap of $7B, and enterprise value of $7B.
Market Cap Evolution
Wantai BioPharm's stock price is $5.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $7B | 0.7% | XXX | XXX | XXX | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialWantai BioPharm Valuation Multiples
Wantai BioPharm trades at 20.8x EV/Revenue multiple, and 123.9x EV/EBITDA.
EV / Revenue (LTM)
Wantai BioPharm Financial Valuation Multiples
As of April 18, 2026, Wantai BioPharm has market cap of $7B and EV of $7B.
Equity research analysts estimate Wantai BioPharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Wantai BioPharm has a P/E ratio of 472.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 20.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 123.9x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 20274.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 31.4x | XXX | XXX | XXX |
| P/E | — | XXX | 472.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (87.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Wantai BioPharm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Wantai BioPharm Margins & Growth Rates
Wantai BioPharm's revenue in the last fiscal year declined by (59%).
Wantai BioPharm's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Wantai BioPharm Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (59%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (77%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 39% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Wantai BioPharm Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Wantai BioPharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Merus | XXX | XXX | XXX | XXX | XXX | XXX |
| ALK | XXX | XXX | XXX | XXX | XXX | XXX |
| Alkem Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Kymera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ono Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wantai BioPharm M&A Activity
Wantai BioPharm acquired XXX companies to date.
Last acquisition by Wantai BioPharm was on XXXXXXXX, XXXXX. Wantai BioPharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Wantai BioPharm
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialWantai BioPharm Investment Activity
Wantai BioPharm invested in XXX companies to date.
Wantai BioPharm made its latest investment on XXXXXXXX, XXXXX. Wantai BioPharm invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Wantai BioPharm
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Wantai BioPharm
| When was Wantai BioPharm founded? | Wantai BioPharm was founded in 1991. |
| Where is Wantai BioPharm headquartered? | Wantai BioPharm is headquartered in China. |
| How many employees does Wantai BioPharm have? | As of today, Wantai BioPharm has over 3K employees. |
| Is Wantai BioPharm publicly listed? | Yes, Wantai BioPharm is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Wantai BioPharm? | Wantai BioPharm trades under 603392 ticker. |
| When did Wantai BioPharm go public? | Wantai BioPharm went public in 2020. |
| Who are competitors of Wantai BioPharm? | Wantai BioPharm main competitors are Merus, ALK, Alkem Laboratories, Kymera Therapeutics. |
| What is the current market cap of Wantai BioPharm? | Wantai BioPharm's current market cap is $7B. |
| What is the current revenue of Wantai BioPharm? | Wantai BioPharm's last fiscal year revenue is $329M. |
| What is the current EV/Revenue multiple of Wantai BioPharm? | Current revenue multiple of Wantai BioPharm is 20.8x. |
| Is Wantai BioPharm profitable? | No, Wantai BioPharm is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.